EvoLiver™
Early detection of liver cancer (HCC) in patients with cirrhosis
Development for FDA ApprovalActive
Key Facts
Indication
Early detection of liver cancer (HCC) in patients with cirrhosis
Phase
Development for FDA Approval
Status
Active
Company
About Mursla Bio
Mursla Bio is a Cambridge-based biotech developing a novel diagnostic platform centered on the isolation and multiomic analysis of organ-specific extracellular vesicles (EVs) from blood. Its lead program, EvoLiver™, targets the critical unmet need for early liver cancer detection in cirrhosis patients and recently received FDA Breakthrough Device Designation. The company's approach combines proprietary EV biology with machine learning to create scalable, blood-based diagnostic assays with potential applications across multiple organ systems and diseases.
View full company profile